Evidence map›Paper›PMID 42618717›Full record

ArticleOncogene2026

Tumor-derived PTX3 drives an immunosuppressive myeloid landscape and inhibits CD8 T cell-mediated anti-tumor immunity via PI3K-dependent signaling.

Mohamed Y Zaky, Monika Vashisht, Mohammad A I Al-Hatamleh, Karen Siddoway, Jennifer Yan, Anthony Bragoli, Jessy John, Huaibin Ge, Zhangguo Chen, Jing H Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohamed Y ZakyUPMC Hillman Cancer Center, Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Monika VashishtUPMC Hillman Cancer Center, Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Mohammad A I Al-HatamlehUPMC Hillman Cancer Center, Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Karen SiddowayUPMC Hillman Cancer Center, Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jennifer YanCMP Program, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0009-0007-7227-1220
Anthony BragoliUPMC Hillman Cancer Center, Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jessy JohnUPMC Hillman Cancer Center, Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Huaibin GeUPMC Hillman Cancer Center, Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Zhangguo ChenUPMC Hillman Cancer Center, Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jing H WangUPMC Hillman Cancer Center, Division of Malignant Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. JHW51@pitt.edu.ORCID http://orcid.org/0000-0003-4343-2527

Funding

Training in Cellular & Molecular Mechanisms of Tumor RejectionT32CA082084 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert J Binder, Dario AA Vignali · 1999 to 2026
$9.2M
U.S. Department of Health & Human Services | National Institutes of Health (NIH) P50-CA097190U.S. Department of Health & Human Services | National Institutes of Health (NIH) T32CA082084
6 · The paper itself

Abstract

Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has emerged as a pillar of modern oncology. However, clinical response rates in head and neck squamous cell carcinoma (HNSCC) remain modest, underscoring the need to identify novel therapeutic targets. Here, we investigated the role of Pentraxin 3 (PTX3) in orchestrating an immunosuppressive tumor microenvironment (TME) in HNSCC. Analysis of the TCGA dataset revealed that elevated PTX3 expression correlates with poor prognosis in HNSCC patients. Moreover, PTX3 is markedly upregulated in aggressive, ICI-resistant TAb2 tumors harboring an activated PIK3CA allele and TP53 deficiency. Using a CRISPR/Cas9 approach to delete PTX3 in TAb2 cells (PTX3-KO), we found that PTX3-KO tumors grew significantly slower than wild-type tumors in vivo. This reduced tumor growth was partially dependent on CD8

Indexed as

CD8-Positive T-LymphocytesC-Reactive ProteinHead and Neck NeoplasmsNerve Tissue ProteinsPhosphatidylinositol 3-KinasesSerum Amyloid P-ComponentSquamous Cell Carcinoma of Head and NeckAnimalsCell Line, TumorClass I Phosphatidylinositol 3-KinasesFemaleHumansLymphocytes, Tumor-InfiltratingMiceMyeloid CellsPentraxinsClass I Phosphatidylinositol 3-KinasesC-Reactive ProteinNerve Tissue ProteinsPentraxinsPhosphatidylinositol 3-KinasesSerum Amyloid P-Component

Identifiers

PMID42618717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.